前列腺癌患者CYP1A2 IVS4＋43A/G基因型分析

目的：应用TaqMan荧光定量技术,了解前列腺癌患者CYP1A2 IVS4＋43A/G位点基因表型。方法：应用ABI Prism7300型荧光定量PCR仪,通过序列检测系统测定85例前列腺癌患者CYP1A2 IVS4＋43A/G的各种基因型,并分析不同基因型患者与前列腺癌分化之间的相关性。结果：85例前列腺癌患者中CYP1A2 IVS4＋43A/G位点基因表型为AA5例（5.9%）,AG33例（38.8%）,GG47例（55.3%）。且各基因表型与前列腺癌Gleason评分无明显相关性。结论：CYP1A2 IVS4＋43A/G各基因表型与前列腺癌分化之间无明显相关性。     

CYP1A2基因多态性与前列腺癌的相关性研究

目的:评价CYP1A2基因单核苷酸多态性(SNPs)与前列腺癌分期分级的相关性。方法:对253例良性前列腺增生(BPH)患者与206例去势前列腺癌患者CYP1A2基因中rs2069514-3859(A>G)位点及rs2069525-1707(C>T)位点进行基因测序,并对各基因表型与前列腺癌的分期分级相关性进行统计学分析。结果:BPH及去势前列腺癌患者的两种CYP1A2单核苷酸多态性的发生率无明显差异(P>0.05),其基因多态性与前列腺癌的病理分期均无相关性(P>0.05);但rs2069525-1707(C>T)中含C等位基因型的前列腺癌Gleason评分多在7分以下(P=0.030,OR=4.658,95%CI:1.222～17.754)。结论:CYP1A2基因的SNPs与前列腺癌的病理分级之间可能有一定的相关性,但其发生机制及临床意义有待进一步证实及研究。     

代谢酶基因多态性与前列腺癌易感性的关系

目的 :探讨CYP1A1、NAT2基因多态性与前列腺癌易感性的关系。　方法 :应用PCR RFLP、ASA和自动实时荧光定量分析技术 ,分析 5 8例前列腺癌病人和 112例健康对照者CYP1A1和NAT2基因 4个位点的多态性 ,比较前列腺癌病人与对照组间频率差异。　结果 :前列腺癌组Ile Val多态位点各等位基因和基因型频率与对照组比较差异有显著性 (P <0 .0 5 ) ,其中等位基因G和GG基因型使患前列腺癌的危险度分别提高了 1.5 9倍 (P <0 .0 5 )和 3.0 6倍 (P <0 .0 5 ) ;前列腺癌组MspI多态位点各等位基因和基因型频率与对照组比较差异无显著性 (P>0 .0 5 )。前列腺癌组NAT2慢乙酰化基因型频率与对照组比较差异无显著性 (P >0 .0 5 )。　结论 :CYP1A1Ile Val基因多态与前列腺癌的发生可能有关 ,MspI基因多态和NAT2慢乙酰化基因型与前列腺癌的发生可能无关     

长春市汉族人群COL1A1启动子区多态性与骨质疏松症的相关性

目的研究长春市汉族人群Ⅰ型胶原α1链基因(COL1A1)启动子区-1997G/T、+1245G/T多态性及其与骨质疏松的关系。方法 (1)抽取受试人群外周静脉血5 ml,提取血清DNA。(2)应用实时荧光定量PCR仪扩增目的基因的DNA片段。(3)采用TaqMan探针法对-1997G/T及+1245G/T位点进行等位基因鉴别。(4)应用双能X线骨密度仪测定骨密度(BMD),将374例受试人群分为骨密度正常、骨质疏松、骨质疏松性骨折3组。结果长春市汉族正常人群COL1A1-1997G/T转换中,GG基因型占38.40%,GT基因型占46.38%,TT基因型占15.22%,以GT基因型为主;骨质疏松患者女性GG等位基因型所占比例大于男性,GG基因型占44.39%,GT基因型占43.37%,TT基因型占12.24%;骨质疏松骨折患者GG基因型为主,占47.50%,GT基因型占35.00%,TT基因型占17.50%。骨质疏松组女性GG基因型BMD低于GT、TT基因型,但差异无统计学意义(P均0.05);骨质疏松骨折组女性GG基因型BMD显著低于GT、TT基因型(P均0.05)。COL1A1+1245位点G/T转换,在正常人群中发现GT杂合型2例,占总数的0.53%,其余均为GG基因型。结论 COL1A1-1997G/T转换中正常人群以GT基因型为主,骨质疏松患者和骨质疏松骨折患者以GG基因型为主。骨质疏松患者和骨质疏松性骨折患者女性GG基因型BMD均低于GT、TT基因型。COL1A1-1997G/T与BMD显著相关,+1245G/T与BMD无相关性。     

CYP1A1与GSTM1基因多态性与前列腺癌易感性的关系

目的　探讨CYP1A1、GSTM1基因多态性与前列腺癌遗传易感性的关系。　方法　采用寡核苷酸芯片对 83例前列腺癌患者和 115例正常对照的中国汉族人群基因组DNA进行CYP1A1、GSTM1基因多态性分析。　结果　GSTM1基因缺失型前列腺癌组占 5 7.8% ,对照组 4 1.7% ,差异有显著性意义 ( χ2 =4 .99,P =0 .0 2 5 ) ,GSTM1null基因型使患前列腺癌的危险度增加 1.9倍 ( 95 %CI=1.10～ 1.34)。GSTM1基因缺失型前列腺癌患者的平均年龄 [( 6 8.1± 8.3)岁 ]低于GSTM1未缺失的患者[( 71.9± 7.4 )岁 ,P =0 .0 31]。前列腺癌组CYP1A1基因的两个多态位点m1、m2基因型频率和等位基因的频率与对照组相比差异无显著性意义 (P >0 .0 5 )。　结论　中国汉族人群GSTM1基因多态性与前列腺癌的发生相关 ,可能是增加前列腺癌危险和发病年龄早的因素之一。CYP1A1基因m1和m2的基因多态与中国汉族人群前列腺癌的发生无相关性     

肾移植受者C YP3A5*3和CYP3A4*18B对他克莫司药动学的影响

目的 探讨肾移植受者细胞色素P4 50酶(CYP)3A5*3、CYP3A4* 18B和CYP3A5-CYP3A4单倍型对他克莫司(Tac)药动学的影响.方法 采用DNA测序法检测61例肾移植受者CYP3A5*3和CYP3A4* 18B基因型.酶联免疫吸附试验测定受者的血Tac浓度,比较术后14d和1、2、3个月时不同基因型受者之间血Tac浓度谷值(G0)、Tac剂量(D)及浓度/剂量(G0/D)的差异.结果 61例中,CYP3A5*3和CYP3A4*18B等位基因突变频率分别为74.6％和26.2％.当CYP3A5表达(*1/*1+*1/*3)者的D是CYP3A5未表达(*3/*3)者的1.3～1.6倍时,未表达者的G0却是表达者的1.1～1.5倍,C0/D是表达者的1.8～2.4倍.CYP3A4* 18B(*1/*18B及*18B/* 18B)基因型者的D是CYP3A4*1/*1基因型者的1.2～1.5倍时,*1/*1基因型者的G0是* 18B基因型者的1.2～1.4倍,G0/D是*18B基因型者的1.5～1.8倍.当CYP3A5-CYP3 A4( AA-AA)者的D是CYP3A5-CYP3A4(GG-GG)者的1.3～1.7倍时,GG-GG的G0是AAAA的1.5～2倍,C0/D是AA-AA的2.5～3倍.当受者G0/D分别位于中位数上下时,CYP3A5、CYP3A4不同基因型和CYP3A5 CYP3A4不同单倍型受者的分布差异较大.结论 肾移植受者CYP3A5*3和CYP3A4* 18B基因多态性对Tac的药动学有显著影响,对CYP3A5 CYP3A4单倍型的分析比单独考虑一种基因型影响更为显著.     

肝移植术后受体他克莫司个体化用药与供体细胞色素P4503A亚家族多肽5和白细胞介素-18基因多态性的关系

目的 探讨肝移植供体细胞色素P4503A亚家族多肽5(CYP3A5)和白细胞介素-18(IL-18)基因多态性与受体术后他克莫司血药浓度/给药剂量的关系.方法 应用测序技术检测84例肝移植患者供体CYP3A5 rs776746和IL-18rs5744247位点单核苷酸多态性,分析基因多态性与他克莫司代谢表型(全血谷浓度/剂量比值,C/D,ng· ml-·mg-·kg-)的相关性.结果 肝移植术后,供体IL-18 rs5744247 GG+ GC基因型患者他克莫司C/D值[(163.1±100.8)ng·ml-1.mg-1·kg-1]明显高于CC基因型患者[116.7±78.2)ng.ml-1·mg-1·kg-1,P＜0.01].移植表达CYP3A5蛋白(*1基因型)供体的患者中,不同供体IL-18基因型患者C/D值(ng.ml-1·mg-1·kg-1) (GG+ GC:133.4±65.3;CC:88.3±39.9)差异有统计学意义(P＜0.05).结论 联合检测供体CYP3A5rs776746和IL-18 rs5744247基因型有助于指导他克莫司个体化用药.     

CYP1A1 rs4646422单核甘酸多态性与中国汉族男性不育的相关性研究

目的:探讨中国汉族男性不育与细胞色素P4501A1基因(CYP1A1)rs4646422位点(GA)单核苷酸多态性之间的相关性。方法:采用病例-对照研究方法,应用Mass ARRAY i PLEX GOLD技术对636例[年龄21~49(29.42±5.09)岁]男性不育患者与442例[年龄23~47(28.62±4.46)岁]正常生育男性的CYP1A1 rs4646422位点进行基因分型,利用SPSS软件统计基因型及等位基因频率在男性不育组和正常生育组中分布特点。结果:与野生纯合型GG比较,杂合型AG(OR=1.06,95%CI:0.81~1.38)和纯合突变型AA(OR=1.11,95%CI:0.56~2.21)与男性不育无相关性。将突变型等位基因A(OR=1.06,95%CI:0.85~1.32)与野生型等位基因G进行比较,同样显示与男性不育无关联。结论:CYP1A1基因(rs4646422)单核甘酸的多态性可能与中国汉族男性不育之间不存在相关性。     

中国汉族男性CYP17基因多态性与前列腺癌发生危险性的关系

目的　探讨CYP1 7基因多态性与前列腺癌发生危险性的关系。　方法　提取 1 2 5例前列腺癌患者和 1 5 8例对照组的血DNA标本 ,设计引物通过PCR技术扩增出包括基因多态位点的片段 ,用限制性内切酶MspA1Ⅰ进行酶切 ,产物在 2 %琼脂糖凝胶上电泳 ,确定出CYP1 7基因的 3种基因型 ,即A1 /A1、A1 /A2、A2 /A2 ,并经测序证实。　结果　基因型A1 /A2、A2 /A2频数与A1 /A1基因型进行比较 ,A1 /A2和A2 /A2在前列腺癌中的频数与对照组相比 ,其OR值分别为 1 .1 9和 1 .2 8,P值分别为 0 .5 7和 0 .4 5 ;但年龄 >6 9岁的病例中 ,其OR值分别为 3.97和 3.2 1 ,P值分别为 0 .0 0 7和 0 .0 2 3;对照组的血fPSA、tPSA水平 3组间差异无显著性意义。　结论　A1 /A2、A2 /A2基因型未增加汉族人群前列腺癌发生的危险性 ,基因型间血PSA水平差异无显著性支持这一观点。年龄 >6 9岁的人群中 ,A1 /A2、A2 /A2基因型显著增加前列腺癌发生的危险性 ,提示CYP1 7基因可能与老年男性前列腺癌发生危险性之间有密切关系     

CYP3A4*1G不同基因型对髋关节置换术后地佐辛复合舒芬太尼自控镇痛效应的影响

目的探讨CYP3A4^*1G多态性对髋关节置换术后地佐辛复合舒芬太尼静脉镇痛效应的影响。方法选取在本院行关节置换术患者150例,男79例,女71例,年龄21~61岁,BMI 16~29 kg/m^2,ASAⅠ或Ⅱ级。根据患者CYP3A4^*1G基因分型检测分为:野生型纯合子(CYP3A4^*1/^*1)基因型组(11组)、突变型杂合子(CYP3A4^*1/^*1G)基因型组(11G组)和突变型纯合子(CYP3A4^*1G/^*1G)基因型组(1G1G组)。所有患者在全麻下行髋关节置换术,术后行地佐辛复合舒芬太尼患者自控镇痛(PCIA)。记录三组患者苏醒即刻、术后12、24和48 h的视觉模拟疼痛(VAS)评分、镇静程度(Ramsay)评分,记录镇静过度的患者例数。记录三组术后0~24和24~48 h地佐辛+舒芬太尼使用量、手术时间和苏醒时间。采用PCR-RFLP对三组患者外周血单核细胞中CYP3A4 mRNA相对表达量进行检测。结果 11组患者93例(62.0%)、11G组患者50例(33.3%)、1G1G组患者7例(4.7%),CYP3A4^*1G最小等位基因频率(MAF)为0.213,等位基因和基因型分布符合Hardy-Weinberg平衡(P=0.933)。三组不同时点VAS评分和Ramsay评分差异无统计学意义,三组均未见镇静过度者。术后0~24 h、24~48 h 1G1G组地佐辛+舒芬太尼使用量明显少于11组和11G组(P<0.05),11组和11G术后0~24 h、24~48 h地佐辛+舒芬太尼使用量差异无统计学意义。三组手术时间和苏醒时间差异无统计学意义。11G组和1G1G组外周血单核细胞中CYP3A4 mRNA相对表达量明显低于11组(P<0.05)。三组恶心呕吐、瘙痒等不良反应发生情况差异无统计学意义。结论与野生型纯合子比较,突变型杂合子和突变型纯合子基因型患者对地佐辛复合舒芬太尼耐受性更低,所需剂量更少。该基因型可作为疼痛个体化治疗的参考指标。     

Polymorphism of cytochrome P450 2B6 and prostate cancer risk: A significant association in a Japanese population

Objectives:   To explore whether Lys262Arg polymorphism of the Cytochrome P450 2B6 (CYP2B6) gene could act as a genetic marker for prostate cancer risk among Japanese men.
Methods:   A total of 350 patients with sporadic prostate cancer and 328 controls were examined. A single nucleotide polymorphism with non-synonymous amino acid change located at Lys262Arg of the CYP2B6 gene was genotyped using a TaqMan assay.
Results:   The frequency of the Arg/Arg genotype among prostate cancer patients was significantly higher than that among the controls ( P  = 0.027). The frequency of the G allele of the Lys262Arg polymorphism was also significantly higher in prostate cancer patients than in the controls (30.4% vs 24.8%, P  = 0.025). Patients with the Lys/Arg plus Arg/Arg genotypes carried a low Gleason score more frequently than those with the Lys/Lys genotype ( P  = 0.042). The frequency of the G allele of the Lys262Arg polymorphism was significantly higher in the low Gleason score group than that in the high Gleason score group (34.3% vs 26.8%, P  = 0.038).
Conclusions:   Lys262Arg polymorphism of the CYP2B6 gene may be a genetic marker for evaluating the risk of sporadic prostate cancer in native Japanese men.     

生物转化酶基因多态性与前列腺癌易感性的研究

目的 探讨生物转化酶类细胞色素P450（CYP）基因CYP1A1m1、m2和谷胱甘肽转硫酶（GST）M1基因多态性与前列腺癌易感性的关系。方法 采用寡核苷酸芯片对83例前列腺癌患者（前列腺癌组）和115例非前列腺癌对照者（对照组）的中国汉族人基因组DNA进行CYP1A1、GSTM1基因多态性分析。结果 GSTM1缺失型在前列腺癌组和对照组均为48例（57．8％,41．7％）,两组比较差异有统计学意义（X^2=4．99,P=0．025）,GSTMl缺失型使患前列腺癌的危险度增加1．9倍（95％CI=1．10～3．40）。GSTM1缺失型随着前列腺癌的分期、分级的提高,其相对危险度明显提高。前列腺癌组CYP1A1基因的两个多态位点m1、m2基因型频率和等位基因的频率与对照组相比均无统计学意义（P〉0．05）。结论 中国汉族人群GSTM1缺失型可能与前列腺癌的发病风险相关,与前列腺癌的分级、分期有关,对临床预测前列腺癌预后可能有一定意义。     

Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men

PURPOSE: Studies suggest that SNPs within ESR1 may be associated with an increased risk of prostate cancer. We evaluated the association of the XbaI and PvuII ESR1 SNPs and prostate cancer risk in 3 different racial/ethnic populations. MATERIALS AND METHODS: A total of 1,603 volunteers from the SABOR study (285 black, 876 white and 442 Hispanic men) were genotyped to assess allelic frequencies of the ESR1 SNPs. Case-control analysis was performed on 598 prostate cancer cases and 1,098 controls (260 black men, 1,013 non-Hispanic white men and 423 Hispanic white men) to assess the association between these polymorphisms and prostate cancer risk. RESULTS: Allelic frequency was significantly different across ethnic/racial groups for both SNPs. Logistic regression analysis adjusted for age and stratified by race and ethnicity demonstrated an association between the AG genotype or presence of the G allele (GG or AG genotype) in the XbaI SNP and prostate cancer risk within black men (OR 2.25, 95% CI 1.07-4.70, p = 0.031; OR 2.14, 95% CI 1.05-4.35, p = 0.035, respectively). No association was observed among Hispanic and non-Hispanic white men for this SNP. Furthermore, there was no association between the PvuII SNP and prostate cancer risk across all groups. CONCLUSIONS: Our study demonstrates an association between the AG genotype, as well as presence of the G allele within the XbaI ESR1 SNP and prostate cancer risk among black men.     

Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men

Genes involved in androgen metabolism are strong candidates for having an important role in the pathogenesis of prostate cancer. CYP3A4, a protein in the cytochrome P-450 supergene family, facilitates the oxidative deactivation of testosterone. In previous studies, patients with the G variant of a genetic polymorphism in CYP3A4 had prostate cancers with clinically aggressive characteristics at diagnosis. The association was strongest among elderly men. We investigated whether the CYP3A4 variant was linked with the diagnosis or clinical presentation of prostate cancer in a case control study of a multiethnic urban population. Biologic specimens were genotyped for CYP3A4, and analyzed for the impact of this genotype on risk and tumor characteristics at presentation, controlling for the effect of several cofactors. The CYP3A4 variant was more common among African-Americans than among white men. Race-stratified analyses revealed little association between the CYP3A4 variant and prostate cancer risk among white men but were limited by the small number of white men with the CYP3A4 variant. Of African-American men, while the variant G allele was not associated with prostate cancer that had less aggressive characteristics, it was associated with risk of aggressive prostate cancer when men with the AG genotype (odds ratio = 9.3, 95% confidence interval 1.3-411) or GG genotype (odds ratio = 11.9 95% confidence interval 1.6-533) were compared with those with the AA genotype. The association between the CYP3A4 genotype and aggressive prostate cancer in African-American men is consistent with findings of other studies.     

Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study

BACKGROUND: Association studies have examined the significance of several candidate genes based on biological pathways relevant to prostate carcinogenesis, including both the androgen and insulin-like growth factor pathways. Clinical and epidemiologic evidence suggest that androgens, specifically testosterone and dihydrotestosterone (DHT) are important not only in normal prostate growth but in the pathogenesis of prostate cancer. Similarly, the insulin-like growth factor-1 (IGF-1) signaling pathway regulates both cellular proliferation and apoptosis. Therefore, genes involved in the biosynthesis, activation, metabolism and degradation of androgens and the stimulation of mitogenic and antiapoptotic activities of prostate epithelial cells represent important candidates for affecting the development and progression of prostate cancer. METHODS: Using resources from the Flint Men's Health Study, a population-based case control study of African-American men aged 40-79, we evaluated the associations between selected single-nucleotide polymorphisms (SNPs) in the CYP17, CYP3A4, CYP19A1, SDR5A2, IGF1, and IGFBP3 genes and prostate cancer diagnosis in 473 men (131 prostate cancer cases and 342 disease-free controls). RESULTS: We found a significant association between prostate cancer and selected CYP17 SNP genotypes, with the heterozygous genotype conferring decreased risk. Suggestive evidence for association between IGF1 SNPs and prostate cancer were also found. No significant associations were observed between SNPs in the other genes and prostate cancer. CONCLUSIONS: These findings suggest that variation in or around CYP17 and/or IGF1 may be associated with prostate cancer development in the African-American population. Additional studies are needed to determine whether these polymorphisms are indeed associated with prostate cancer risk in African Americans.     

The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men

AIM: Since catechol estrogens possess carcinogenetic potential, their detoxification may lead to reduced risk of carcinogenesis. Catechol-O-methyltransferase (COMT) catalyzes the O-methylation of catechol estrogens. The enzymatic activity of COMT has been shown to be governed by a functional single-nucleotide polymorphism represented by a G-to-A transition at codon 158, that results in a valine to methionine substitution; this variant form is associated with an up to 4-fold decrease in enzymatic activity. We attempted to investigate whether the Val158Met polymorphism of COMT was associated with the risk of prostate cancer. METHODS: We analysed genomic DNA samples from 324 sporadic prostate cancer patients; 342 controls who had died from causes unrelated to cancer; and 95 Japanese men who were diagnosed as latent prostate cancer by autopsy. The genotyping method we used was a TaqMan assay. RESULTS: Age adjusted odds ratios for sporadic prostate cancer susceptibility were 1.047 (95% CI: 0.630-1.741) for the G/A genotype and 0.858 (95% CI: 0.407-1.804) for the A/A genotype, as compared with those for the G/G genotype. There was no significant association between this polymorphism and latent prostate cancer susceptibility either. CONCLUSIONS: Our results suggested that the Val158Met polymorphism of COMT was not associated with the risk of sporadic or latent prostate cancer in Japanese men.     

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer

PurposePolymorphisms in the CYP19A1 (aromatase) gene have been reported to influence disease-free survival and the incidence of musculoskeletal complaints in patients taking aromatase inhibitors (AIs) for estrogen receptor positive (ER +) breast cancer. Bone loss and fractures are well-recognized complications from AI therapy. The objective of this study is to determine the influence of polymorphisms in the CYP19A1 gene on bone loss among patients taking aromatase inhibitors for ER + breast cancer.Patients and methodsThe subjects consisted of 97 postmenopausal women with ER + breast cancer who were initiated on third-generation AIs. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry at baseline and at 6 and 12 months. Twenty-four hour urine N-telopeptide (NTX) was measured by Elisa and serum estradiol was measured by ultrasensitive radioimmunoassay at baseline, and at 6 months. Genotyping was done by Taqman SNP allelic discrimination assay.ResultsWomen with the AA genotype for the rs700518 (G/A at Val⁸⁰) developed significant bone loss at the lumbar spine and the total hip at 12 months relative to patients carrying the G allele (GA/GG); both p = 0.03. There was a borderline greater increase in urinary NTX in those with the AA genotype compared to patients with the G allele, p = 0.05; but no significant difference in changes in estradiol levels among the genotypes.ConclusionPatients with the AA genotype for the rs700518 polymorphism in the CYP19A1 gene are at risk for AI-associated bone loss and deserve close follow-up during long-term AI therapy.     

Genetic polymorphisms in the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and prostate cancer susceptibility: A case-control study in a Han nationality population in Southern China

AIM: To investigate the association among the polymorphisms of the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and the risk of prostate cancer (PCa) in a Han nationality population in Southern China. METHODS: A case-control study including 225 PCa patients and 250 age-matched controls was conducted. The six polymorphic sites of the CYP 1A1 and CYP2E1 genes were analysed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) or allele-specific PCR technique using genomic DNA isolated from peripheral blood lymphocytes. RESULTS: We found that the CYP1A1 Val/Val genotype significantly increased the risk for PCa (OR, 2.26; 95% CI, 1.09-4.68). In contrast, the CYP2E1 C1/C2 (OR, 0.67; 95% CI, 0.46-0.99) or C2/C2 genotype (OR, 0.31; 95% CI, 0.10-1.00) significantly decreased the risk. Furthermore, the individuals carrying the CYP1A1 Val allele and the CYP2E1 C1/C1 genotype showed the highest risk (OR, 2.50; 95% CI, 1.45-4.29). Though there was no significant difference with smoking history (P = 0.237) or drinking habit (P = 0.499) between cases and controls, a deep smoking habit (OR, 2.02; 95% CI, 1.28-3.17) and heavy smoking history (OR, 1.61; 95% CI, 1.04-2.50) significantly increased the susceptibility of PCa after stratification by smoking method and accumulative smoking amount. Moreover, both the CYP1A1 Val allele (OR, 2.82; 95% CI, 1.49-5.35) and CYP2E1 C1/C1 genotype (OR, 2.57; 95% CI, 1.31-5.02) had obvious interaction with heavy smoking history that significantly raised the risk. We also discovered a significant interaction between the CYP2E1 C1/C1 genotype and drinking (OR, 1.85; 95% CI, 1.04-3.28). CONCLUSIONS: Individuals carrying the CYP1A1 Val allele or the CYP2E1 C1/C1 genotype with a smoking or drinking habit were at increased risk of PCa, which also showed a positive correlation with exposure dose of tobacco.